Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01751438 | Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) | completed | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 27, 2023 | clinicaltrials |
| NCT02159950 | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02624518 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 122 | Andrei IagaruOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05806853 | PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study | completed | Phase 2 | 60 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02278055 | Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03679260 | Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance | completed | Phase 2 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03103152 | A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression(PROVENT) | completed | Phase 2 / Phase 3 | 104 | Queen Mary University of LondonOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04179968 | The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer | completed | Phase 2 | 20 | Dana MathewsOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01385059 | Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer | completed | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03043807 | A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04627896 | Targeted Microwave Focal Therapy | completed | Phase 2 / Phase 3 | 11 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01903408 | Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment(PLATIN) | completed | Phase 2 | 199 | Heidelberg UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02311049 | Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01921803 | Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer(Hypofraction) | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT00547339 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 94 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02680587 | Stereotactic Body Radiation for Prostate Oligometastases(ORIOLE) | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03114254 | A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis(JAVA-P) | completed | Phase 2 | 17 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT02598895 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | completed | Phase 2 | 14 | University of WashingtonOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02649439 | Prostvac in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02176161 | Metformin Prostate Cancer Adjuvant Trial | completed | Phase 2 | 59 | NYU Langone HealthOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01717053 | Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer | completed | Phase 2 | 37 | Duke UniversityOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT02789878 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | completed | Phase 2 | 64 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | completed | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02716974 | A Study of Definitive Therapy to Treat Prostate Cancer(oligo-mets) | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04424654 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy(PSMA-BAT) | completed | Phase 2 | 20 | Hospital Sirio-LibanesOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT02090114 | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)(Restore) | completed | Phase 2 | 112 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00450411 | Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy | completed | Phase 2 | 100 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02770391 | Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer | completed | Phase 2 | 54 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT00726596 | Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 64 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer(TheraP) | completed | Phase 2 | 201 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT01434290 | Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 255 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT04475016 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | completed | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03373006 | A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer | completed | Phase 2 | 20 | HALO DiagnosticsINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT00964002 | Efavirenz in Treating Patients With Metastatic Prostate Cancer(FAVE) | completed | Phase 2 | 61 | Institut BergoniéOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02268175 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02614859 | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients(BIMET-1) | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01630590 | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT02353832 | Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer | completed | Phase 2 | 44 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT00828308 | Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | completed | Phase 2 | 16 | Brown UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02678351 | 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery | completed | Phase 2 / Phase 3 | 74 | Andrei IagaruOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04862091 | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2023source: clinicaltrials